Marker-independent Method for Isolating Slow-Dividing Cancer Stem Cells in Human Glioblastoma

• Published in: Neoplasia (New York, N.Y.) N.Y.), 2013-07, Vol.15 (7), p.840-IN39
• Main Authors: Richichi, Cristina, Brescia, Paola, Alberizzi,, Valeria, Fornasari, Lorenzo, Pelicci, Giuliana
• Format: Article
• Language: English
• Subjects: Animals; Antigens, Surface - metabolism; Brain Neoplasms - genetics; Brain Neoplasms - metabolism; Cell Cycle; Cell Separation - methods; Cell Transformation, Neoplastic - genetics; Cell Transformation, Neoplastic - metabolism; Flow Cytometry; Glioblastoma - genetics; Glioblastoma - metabolism; Heterografts; Humans; Immunophenotyping; Mice; Neoplastic Stem Cells - cytology; Neoplastic Stem Cells - metabolism; Neoplastic Stem Cells - transplantation; Oncology; Organic Chemicals - metabolism; Spheroids, Cellular; Transcriptome; Tumor Cells, Cultured; Tumor Stem Cell Assay
• ISSN: 1476-5586; 1522-8002; 1476-5586; 1522-8002
• DOI: 10.1593/neo.13662

Abstract Glioblastoma (GBM) is a devastating brain tumor with a poor survival outcome. It is generated and propagated by a small subpopulation of rare and hierarchically organized cells that share stem-like features with normal stem cells but, however, appear dysregulated in terms of self-renewal and proliferation and aberrantly differentiate into cells forming the bulk of the disorganized cancer tissues. The complexity and heterogeneity of human GBMs underlie the lack of standardized and effective treatments. This study is based on the assumption that available markers defining cancer stem cells (CSCs) in all GBMs are not conclusive and further work is required to identify the CSC. We implemented a method to isolate CSCs independently from cell surface markers: four patient-derived GBM neurospheres containing stem, progenitors, and differentiated cells were labeled with PKH-26 fluorescent dye that reliably selects for cells that divide at low rate. Through in vitro and in vivo assays, we investigated the growth and self-renewal properties of the two different compartments of high- and slow-dividing cells. Our data demonstrate that only slow-dividing cells retain the ability of a long-lasting self-renewal capacity after serial in vitro passaging, while high-dividing cells eventually exhaust. Moreover, orthotopic transplantation assay revealed that the incidence of tumors generated by the slow-dividing compartment is significantly higher in the four patient-derived GBM neurospheres analyzed. Importantly, slow-dividing cells feature a population made up of homogeneous stem cells that sustain tumor growth and therefore represent a viable target for GBM therapy development.